Telmisartan 40mg Tablet (VICARDIS*) 30s

97.00

Out of stock

SKU: 11162023151112 Category:

Description

Indications

Listed in Dosage.

Dosage

Adult : PO HTN Initial: 40 mg once daily, may be adjusted to 20-80 mg once daily. CV risk reduction 80 mg once daily.

Dosage Details

Oral
Hypertension

Adult: Initially, 40 mg once daily, may be adjusted to 20-80 mg once daily if needed.

Oral
Cardiovascular risk reduction

Adult: 80 mg once daily.

Renal Impairment

Severe impairment or on haemodialysis: Initially, 20 mg once daily.

Hepatic Impairment

Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated.

Administration

May be taken with or without food.

Contraindications

Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Severe hepatic impairment. Pregnancy.

Special Precautions

Volume- or salt-depleted patients including patients on prolonged diuretic therapy. Patients w/ renal artery stenosis, aortic or mitral stenosis, obstructive biliary disease. Renal and mild to moderate hepatic impairment. Lactation.

Adverse Drug Reactions

Dizziness, fatigue, headache, sinusitis, upper resp tract infection, pharyngitis, UTI, back pain, myalgia, diarrhoea, abdominal pain, dyspepsia, nausea.
Potentially Fatal: Intermittent claudication and skin ulcer.

Pregnancy Category (US FDA)

PO: D

Monitoring Parameters

Monitor BP, electrolytes and serum creatinine levels.

Overdosage

Symptoms: Hypotension, bradycardia, tachycardia, dizziness, acute renal failure and elevated serum creatinine. Management: Supportive and symptomatic treatment. Induction of emesis and/or gastric lavage. Activated charcoal may be useful. Salt and volume replacement should be given immediately if hypotension occurs and place patient in supine position.

Drug Interactions

May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). 

Food Interaction

Food may slightly decrease the bioavailability.

Mechanism of Action

Description: Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.
Onset: 1-2 hr.
Duration: Up to 24 hr.
Pharmacokinetics: 
Absorption: Rapidly absorbed from the GI tract. Food may slightly decrease the bioavailability. Absolute bioavailability: Dose-dependent (approx 42% after 40-mg dose; 58% after 160-mg dose). Time to peak plasma concentration: Approx 0.5-1 hr.
Distribution: Volume of distribution: 500 L. Plasma protein binding: >99%.
Metabolism: Undergoes conjugation w/ glucuronic acid to form inactive metabolites.
Excretion: Via faeces (97%, as unchanged drug). Terminal elimination half-life: Approx 24 hr.

Storage

Store at 25°C.

MIMS Class

Angiotensin II Antagonists

Additional information

location

davao, cdo, dipolog, butuan